- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
- Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
More ▼
Key statistics
As of last trade Chemomab Therapeutics Ltd (CMMB:NAQ) traded at 1.23, -30.40% below its 52-week high of 1.77, set on Jun 21, 2023.
52-week range
Open | 1.24 |
---|---|
High | 1.31 |
Low | 1.21 |
Bid | 1.23 |
Offer | 1.25 |
Previous close | 1.22 |
Average volume | 146.78k |
---|---|
Shares outstanding | 14.22m |
Free float | 13.54m |
P/E (TTM) | -- |
Market cap | 15.21m USD |
EPS (TTM) | -26.80 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 16:39 BST.
More ▼